Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05036083 · ClinicalTrials.gov registry record · NA
Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 89
- Enrollment target
NCT05036083: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT05036083 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 89 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05036083, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 89 participants
- Enrollment target
Study Summary
This clinical trial investigates contrast-enhanced mammography (CEM) in detecting breast cancer. CEM is similar to standard mammography, but it includes an injection of an iodine-based contrast, which makes tissue and blood vessels more visible in scans. Diagnostic procedures, such as CEM, may increase the chance of finding breast cancers and decrease the risk of having unnecessary biopsies.
Primary Outcome
Rate of malignancy in lesions de-novo detected on CEM at MDACC and not detected on outside facility imaging. New non-index lesions detected on CEM that had a benign/malignant outcome on image-guided biopsy, surgery, or had a 24-month imaging follow-up with no cancer development (lesion-level evaluation) \*Index lesion was defined as follows: A) Known cancer detected at an outside facility B) Highly suspicious imaging lesion detected at an outside facility, for which a consultation was requested
Interventions
- OTHER Electronic Health Record Review
- PROCEDURE Contrast-Enhanced Mammography
- PROCEDURE Digital Tomosynthesis Mammography
- DRUG Iodinated Contrast Agent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2021-03-19 |
| Est. Completion | 2024-03-25 |
| Phase | NA |
What the finished NCT05036083 record still lists
NCT05036083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 4 interventions - of which Electronic Health Record Review is the first listed.
NCT05036083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05036083 about?
NCT05036083 is a clinical study titled "Contrast-Enhanced Mammography for Breast Cancer Staging in Patients Referred for a Second Opinion". This clinical trial investigates contrast-enhanced mammography (CEM) in detecting breast cancer. CEM is similar to standard mammography, but it includes an injection of an iodine-based contrast, which makes tissue and blood vessels more visible in scans. Diagnostic procedures, such as CEM, may incre...
What is the current status of trial NCT05036083?
This trial is currently completed. It is a NA study. The enrollment target is 89 participants. The study started on 2021-03-19. Estimated completion is 2024-03-25.
What interventions are being tested in trial NCT05036083?
The interventions under investigation include: Electronic Health Record Review (OTHER), Contrast-Enhanced Mammography (PROCEDURE), Digital Tomosynthesis Mammography (PROCEDURE), Iodinated Contrast Agent (DRUG).
Who is sponsoring clinical trial NCT05036083?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05036083's enrollment target sits among peer trials
89 972nd of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI